


## Data Sheet

<b>Product Name:</b>	Remetinostat
<b>Cat. No.:</b>	CS-0018698
<b>CAS No.:</b>	946150-57-8
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>21</sub> NO <sub>6</sub>
<b>Molecular Weight:</b>	323.34
<b>Target:</b>	HDAC
<b>Pathway:</b>	Cell Cycle/DNA Damage; Epigenetics
<b>Solubility:</b>	DMSO : 150 mg/mL (463.91 mM; Need ultrasonic)



### BIOLOGICAL ACTIVITY:

Remetinostat (SHP-141) is a hydroxamic acid-based inhibitor of **histone deacetylase enzymes (HDAC)** which is under development for the treatment of cutaneous T-cell lymphoma<sup>[1]</sup>. IC<sub>50</sub> & Target: HDAC<sup>[1]</sup>.

### References:

[1]. Yijun Deng, et al. Process Development of the Soft Histone Deacetylase Enzyme Inhibitor SHP-141: Acylation of Methyl Paraben and Suberyl Hydroxamic Acid Formation. Org. Process Res. Dev. 2016, 20, 10, 1812-1820.

### CAIndexNames:

Benzoic acid, 4-[[8-(hydroxyamino)-1,8-dioxooctyl]oxy]-, methyl ester

### SMILES:

O=C(OC)C1=CC=C(OC(CCCCCC(NO)=O)=O)C=C1

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA